Bonds Investor

Bond Biosciences is a clinical-stage biopharmaceutical company focused on developing first-in-class, non-absorbed oral therapeutics. The company's technology platform utilizes proprietary polymers designed to bind excess ions locally within the gastrointestinal tract, preventing their systemic absorption and treating metabolic and orphan diseases. Its lead program, BND-101, is being developed for the treatment of hyperoxaluria, while BND-102 targets iron overload in patients with hereditary hemochromatosis. By restricting drug activity to the GI tract, Bond Biosciences aims to provide potent therapeutic effects with a high safety profile and minimal systemic side effects.